Hospital De Galdakao Usansolo

The hematology department at Hospital De Galdakao Usansolo is dedicated to advancing care for blood‑related cancers and disorders through innovative therapeutic strategies.

• Evaluation of new targeted agents for acute myeloid leukemia
• Investigation of combination regimens in mantle cell lymphoma
• Assessment of autologous transplantation approaches following novel induction therapies
• Exploration of maintenance strategies to improve long‑term remission rates

With 35 active studies and a team of 29 investigators, the site contributes robust data to the field of hematologic oncology.

Research at the site spans a broad spectrum of solid tumors, emphasizing personalized medicine and combination treatments to enhance survival outcomes.

• Testing PI3K inhibition in HER2‑positive breast cancer with PIK3CA mutations
• Comparing antibody‑drug conjugates versus standard care in triple‑negative breast cancer
• Evaluating neoadjuvant chemotherapy plus immunotherapy for early‑stage breast disease
• Studying novel regimens for locally advanced colon cancer and metastatic pancreatic adenocarcinoma

The oncology portfolio reflects a commitment to integrating targeted agents, immunotherapies, and innovative delivery systems.

The department conducts multiple trials aimed at improving outcomes for chronic and acute lung conditions, focusing on both disease modification and symptom relief.

• Assessing antifibrotic therapy to slow progression in idiopathic pulmonary fibrosis and other progressive ILDs
• Evaluating cough reduction agents for patients with progressive pulmonary fibrosis
• Testing inhaled combination therapy versus standard LABA‑LAMA in high‑risk COPD patients
• Investigating reduced‑dose thrombolytics for intermediate‑high‑risk acute pulmonary embolism

These studies address unmet needs in lung health, from fibrosis to exacerbations, using novel pharmacologic and procedural approaches.

Clinical investigations target arterial and venous disorders, aiming to refine acute management and long‑term vascular health.

• Optimizing antiplatelet strategies in acute coronary syndrome with platelet function testing
• Evaluating oxygen therapy as an adjunct in acute pulmonary embolism
• Studying venous valve grafts to reduce pathology in severe chronic venous insufficiency
• Implementing iron supplementation to lower transfusion rates in patients with anemia undergoing revascularization surgery

The cardiovascular program integrates pharmacologic, procedural, and device‑based solutions to improve patient outcomes.

The site’s gastroenterology research focuses on inflammatory bowel disease and gastrointestinal malignancies, testing both biologic and small‑molecule therapies.

• Induction and maintenance trials of novel agents in moderate‑to‑severe Crohn’s disease
• Phase III assessment of oral mesalazine for remission in active ulcerative colitis
• Combination strategies for improving remission rates in ulcerative colitis with obesity or overweight
• Evaluating targeted therapies for locally advanced colon cancer and metastatic pancreatic cancer

By addressing both inflammatory and neoplastic conditions, the research aims to expand therapeutic options for digestive health.

Trials in autoimmunity explore biologic agents that modulate disease activity and improve quality of life for patients with systemic disorders.

• Dose‑response studies of novel biologics in systemic lupus erythematosus
• Evaluating long‑term safety of oral agents for fibrotic lung disease linked to autoimmune mechanisms
• Assessing the impact of combined biologic therapy on disease activity in refractory autoimmune conditions

The immune‑focused program seeks to translate mechanistic insights into effective, patient‑centric treatments.

Endocrine research at the center addresses metabolic and thyroid disorders, with an emphasis on cardiovascular risk reduction and quality of life.

• Combination of vicadrostat and empagliflozin to lower cardiovascular events in patients with type 2 diabetes and hypertension
• Impact of levothyroxine therapy on erectile function in individuals with subclinical hypothyroidism
• Weight‑loss outcomes when pairing anti‑inflammatory biologics with metabolic agents in obese patients

These studies integrate hormonal regulation with cardiovascular and sexual health considerations.

Focused investigations aim to improve sexual health outcomes through endocrine modulation and targeted therapies.

• Assessing the effect of levothyroxine adjustment on erectile function in men with hypothyroidism
• Evaluating patient‑reported outcomes related to sexual activity and satisfaction during treatment

The research underscores the importance of addressing urogenital health as part of comprehensive patient care.

Additional trials explore behavioral and metabolic factors that influence disease risk and treatment response.

• Smoking cessation program evaluating safety and efficacy of extended‑duration cytisinicline
• Interventions targeting obesity and overweight in conjunction with inflammatory bowel disease therapy
• Supplemental oxygen strategies for acute pulmonary embolism to improve short‑term outcomes

By integrating lifestyle modifications with pharmacologic approaches, the site broadens its impact on overall health.